<qa>  What is the pathological complete remission rate in patients with non HER2neu breast- Compare 2 neoadjuvant chemotherapy regimens docetaxel, doxorubicin hydrochloride, and cyclophosphamide TAC vs doxorubicin and cyclophosphamide followed by paclitaxel and carboplatin ACAC, in terms of toxicities and effectiveness as defined by the pathological complete remission rate, in patients with non HER2neu overexpressing stage II or III breast cancer. 